Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.

In an assessment of 9 clinics and 166 users spanning from nurses, medical assistants, and advanced practice clinicians to physicians, the majority of nurses — about 92 percent — felt an AI chatbot ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Hims & Hers Health shares rose Monday after the Food and Drug Administration said compounding pharmacies could continue to ...

Eli Lilly also announced the FDA approval of its new eczema treatment, EBGLYSS, based on results from three clinical studies. The company's strategic decisions to expand its drug manufacturing ...

Eli Lilly will invest $4.5 billion to construct the Lilly Medicine Foundry, a center aimed at finding better ways to make medicines. The investment seeks to build upon Lilly's success from ...